Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting
Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…Abstract Number: 2872 • 2018 ACR/ARHP Annual Meeting
Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
Background/Purpose: The identification of risk factors associated with flares in RA is challenging because of the use of different composite disease activity scores and a…Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…Abstract Number: 2890 • 2018 ACR/ARHP Annual Meeting
Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
Background/Purpose: Although recent treatment guideline of axial spondyloarthritis (axSpA) by the European League Against Rheumatism (EULAR) recommended that tapering of tumor necrosis factor inhibitor (TNFi)…Abstract Number: 1191 • 2018 ACR/ARHP Annual Meeting
The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care
Background/Purpose: Quantitative measures such as laboratory tests and pooled indices have advanced clinical rheumatology care far beyond narrative decisions. These measures generally are directed to…Abstract Number: 1601 • 2018 ACR/ARHP Annual Meeting
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States
Background/Purpose: In patients (pts) with psoriatic arthritis (PsA), early diagnosis and effective treatment has been shown to decrease functional disability and structural progression (Gladman DD,…Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…Abstract Number: 95 • 2017 ACR/ARHP Annual Meeting
Globalisation of Paediatric Musculoskeletal Matters’ (PMM)
Background/Purpose: paediatric musculoskeletal matters’ (PMM–www.pmmonline.org) is a free, evidence-based and peer reviewed open e-resource for paediatric musculoskeletal (MSK) medicine targeting non-MSK specialists. Since launch (Nov-2014)…Abstract Number: 1511 • 2017 ACR/ARHP Annual Meeting
Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis
Background/Purpose: The ASAS Health Index (ASAS HI) have been developed to measure health and impairment in functioning in patients with spondyloarthritis (SpA). Its measurement properties…Abstract Number: 186 • 2017 ACR/ARHP Annual Meeting
Paediatric Musculoskeletal (MSK) Triage in the Community – Rightpath – a Pilot Study
Background/Purpose: We are piloting a children and young people (CYP) community-based triage (called Rightpath) based on a validated adult MSK triage model developed by Pennine…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »